Medical Oncology

, Volume 16, Issue 1, pp 13–16 | Cite as

Will modern cancer vaccines reach clinical practice?



immunotherapy vaccine dendritic cells 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berd DMHet al. Treatment of metastatic melanoma with an autologous tumour cell vaccine: clinical and immunologic results in 64 patients.J Clin Oncol 1997;8: 1958–1967.Google Scholar
  2. 2.
    Rosenberg SA. Development of cancer immunotherapies based on identification of genesencoding cancer regression antigens.J Natl Cancer Inst 1996;88: 1635–1644.PubMedCrossRefGoogle Scholar
  3. 3.
    Fernandez NDM, Perricaudet M, Lotze M, Tursz T, Zitvogel L. Active specific T-cell-based immunotherapy for cancer: nucleic acid, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.Cytok, Cell Mol Ther 1998;4: 53–65.Google Scholar
  4. 4.
    Zinkernagel RMESet al. Antigen localisation regulates immune responses in a dose and time dependent fashion: a geographical view of immunerectivity.Immunol Rev 1997;156: 199–200.PubMedCrossRefGoogle Scholar
  5. 5.
    Matzinger P. Tolerance danger and the extended family.Ann Rev Immunol 1994;12: 991–1045.CrossRefGoogle Scholar
  6. 6.
    Dranoff GMR. Genetransfer as cancer therapy.Adv Immunol 1995;58: 417–454.PubMedCrossRefGoogle Scholar
  7. 7.
    Gilboa ENS, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines.Cancer Immunol Immunother 1998;46: 82–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Nestle Fet al. Vaccination of melanoma patients with peptide- or tumour lysate-pulsed dendritic cells.Nat Med 1998;4(3): 328–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosenberg SYJet al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.Nat Med 1998;4(3): 321–327.PubMedCrossRefGoogle Scholar
  10. 10.
    Marchand Met al. Regressions observed in metastatic melanoma of patients treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.Int J Cancer 1999;80(2): 459–469.CrossRefGoogle Scholar

Copyright information

© Stockton Press 1999

Authors and Affiliations

  1. 1.Department of Oncology and Immuno-gene therapy LaboratoryKarolinska HospitalStockholmSweden

Personalised recommendations